诺葆安

Nuobaoan (Beijing) Biotechnology is a Chinese biopharmaceutical company specializing in the development of innovative mRNA-based vaccines and therapeutics. Headquartered in the Beijing Daxing Bio-medicine Industry Park, the company leverages its proprietary mRNA synthesis and lipid nanoparticle (LNP) delivery platforms to address infectious diseases. Its research and development pipeline primarily focuses on high-impact viral pathogens, including respiratory syncytial virus (RSV), shingles (varicella-zoster virus), and seasonal influenza. Nuobaoan aims to provide high-quality, scalable, and affordable vaccine solutions by integrating advanced molecular biology with optimized formulation technologies. The company is currently advancing several candidates through pre-clinical development and IND-enabling studies to support future clinical trials.